News
02-08-2024, 11:57 PM
A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor has anti-tumour effects in estrogen receptor positive breast cancer patients.
More... (https://www.news-medical.net/news/20240208/Selective-androgen-receptor-modulator-has-anti-tumor-effects-in-ER-positive-breast-cancer-patients.aspx)
More... (https://www.news-medical.net/news/20240208/Selective-androgen-receptor-modulator-has-anti-tumor-effects-in-ER-positive-breast-cancer-patients.aspx)